CHRNA7 and ischemia: The therapeutic utility of PAM-II-based strategies is supported by the ubiquitous expression of α7 nAChRs in the brain and especially, in the brain regions that are selectively vulnerable to ischemia, such as cortex, striatum and hippocampus [63–66].